Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03757910 · ClinicalTrials.gov registry record · Early Phase 1
Brain Imaging in the Diabetes Prevention Program Outcomes Study
A Early Phase 1 study, sponsored by José A. Luchsinger.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT03757910 is a Early Phase 1 study that was terminated before completion, run by José A. Luchsinger. The registered enrollment target is 5 participants.
The verdict
NCT03757910, a Early Phase 1 study, was terminated before completion, sponsored by José A. Luchsinger.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a cross-sectional pilot study of Alzheimer's disease (AD) brain imaging biomarkers in Diabetes Prevention Program (DPP) outcomes study (DPPOS) participants from the New York City sites (Columbia and Einstein), comparing 10 persons originally randomized to metformin and 10 persons randomized to placebo in DPP. All study procedures will be conducted at Columbia University Irving Medical Center. Eligible participants will receive a PET scans and a brain MRI, which may be conducted in one, two, or three separate visits.
Interventions
- DRUG 18F-MK-6240
- DRUG 11C-PIB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2023-01-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03757910
The ClinicalTrials.gov registry entry for NCT03757910 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is José A. Luchsinger, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 18F-MK-6240 is the first listed.
NCT03757910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03757910 about?
NCT03757910 is a clinical study titled "Brain Imaging in the Diabetes Prevention Program Outcomes Study". This is a cross-sectional pilot study of Alzheimer's disease (AD) brain imaging biomarkers in Diabetes Prevention Program (DPP) outcomes study (DPPOS) participants from the New York City sites (Columbia and Einstein), comparing 10 persons originally randomized to metformin and 10 persons randomized ...
What is the current status of trial NCT03757910?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2019-10-01. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT03757910?
The interventions under investigation include: 18F-MK-6240 (DRUG), 11C-PIB (DRUG).
Who is sponsoring clinical trial NCT03757910?
This trial is sponsored by José A. Luchsinger, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.